Kong, Anthony http://orcid.org/0000-0002-3989-3948
Mehanna, Hisham
Article History
Accepted: 20 May 2021
First Online: 16 July 2021
Declarations
:
: A.K. received fees for consulting, advisory, speaker’s roles, and/or research funding from PUMA BioTechnology, AstraZeneca, Merck, MSD, Bristol-Myers Squibb, and Avvinity Therapeutics. H.M. has personal financial interests with AstraZeneca, MSD, GSK, Sanofi Pasteur, Merck, and Warwickshire Head Neck Clinic Ltd; institutional financial interests with AstraZeneca, GSK PLC, Sanofi Pasteur, MSD, GSK Biologicals, and Silence Therapeutics; and leadership roles: Chief of Liteform Trial Steering Committee, Chair of NIMRAD Trial Steering Committee, President of the British Association of Head Neck Oncologists, Trial Steering Group member of the MRC CTU Cancer Trials Steering Committee, Council member of the International Association of Oral Oncology, Director of the Institute for Head Neck Studies and Education, Secretary of the Head Neck Cancer InterGroup. H.M. is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care.